Business
– Teva will receive $72 million from future sales or from the proceeds of an exit, if any. Diapep277 Slowing the Progression of Type 1...
Hi, what are you looking for?
– Teva will receive $72 million from future sales or from the proceeds of an exit, if any. Diapep277 Slowing the Progression of Type 1...
– Following the sale, Phillip Frost still owns Teva shares worth more than $500 million. – Phillip Frost / Getty – Teva Pharmaceutical Industries...
– The burn and wound treatment company MediWound plans to raise $100m on Nasdaq at a $400 million valuation. – In the coming weeks, several Israeli...
– Teva expects the Supreme Court to hear the case in April, a month before the Copaxone patents expire. – Teva Pharmaceutical Industries Ltd. (NYSE: TEVA;...
– In a notice to the SEC, biotech company NuPathe said that Teva is offering $3.65 per share, compared with yesterday’s closing price of...
– Teva’s board is due to meet within days to approve Erez Vigodman’s appointment as CEO. – – Erez Vigodman, 54, a board member...
– In an email to investors seen by the “Financial Times, ” printing pioneer Benny Landa hints he is seeking to oust Teva chairman...
– Brig-Gen (res.) Gil Hirsch claims he is owed the money for mediating Teva’s acquisition of Cephalon. Brigadier General (res.) Gil Hirsch filed a...
– ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), reported that it has acquired 31 previously marketed generic drug products from Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) for...
– Law firm Rigrodsky & Long has filed a class action lawsuit in the US District Court for the Southern District of New York....